Psilocybin -Therapie im Zusammenhang mit einer dauerhaften Depression Remission fünf Jahre später | Die Forschung legt nahe, dass die Kombination der psychedelischen Substanz mit Psychotherapie zu dauerhaften Verbesserungen der psychischen Gesundheit und des allgemeinen Wohlbefindens führen kann.
Psilocybin therapy linked to lasting depression remission five years later
6 Kommentare
From the article: A new long-term follow-up study has found that a significant majority of individuals treated for major depressive disorder with psilocybin-assisted therapy were still in remission from their depression five years later. The research, which tracked participants from an earlier clinical trial, suggests that the combination of the psychedelic substance with psychotherapy can lead to lasting improvements in mental health and overall well-being. The findings were [published](https://akjournals.com/view/journals/2054/aop/article-10.1556-2054.2025.00461/article-10.1556-2054.2025.00461.xml) in the Journal of Psychedelic Studies.
Psilocybin is the primary psychoactive compound found in certain species of mushrooms, often referred to as “magic mushrooms.” When ingested, it can produce profound alterations in perception, mood, and thought. In recent years, researchers have been investigating its potential as a therapeutic tool when administered in a controlled clinical setting alongside psychological support.
The rationale for this line of research stems from the limitations of existing treatments for major depressive disorder. While many people benefit from conventional antidepressants and psychotherapy, a substantial portion do not achieve lasting remission, and medications often come with undesirable side effects and require daily, long-term use.
Psychedelic-assisted therapy represents a different treatment model, one where a small number of high-intensity experiences might catalyze durable psychological changes. This new study was conducted to understand the longevity of the effects observed in an earlier, promising trial.
The research team, led by Alan Davis, an associate professor and director of the Center for Psychedelic Drug Research and Education at The Ohio State University, sought to determine if the initial antidepressant effects would hold up over a much longer period. Davis co-led the original 2021 trial at Johns Hopkins University, and this follow-up represents a collaborative effort between researchers at both institutions.
The best thing about using psilocybin to me, is that you can tap back into that feeling you had during the trip months later. When I start feeling down I think about the feelings and thoughts I experienced and it always grounds me to what is the truth as far as I can understand it.
I’ve done other psychedelics like L.S.D., but it doesn’t have the same lasting positive effect in my experience.
I often wonder how I got here – happy family life, new son, homeowner, doing fine in this economy – from the angry industrial goth-punk person I was when I was younger, and then posts like this remind me that „oh yeah, I did have a couple of extremely positive MDMA experiences in the early 2000s that completely rewired my brain.“
I’m sure that for every good story there’s also a bad one, but in my books psychedelics (and good company!) saved my life
Not sure whether it works slightly different with my audhd neurotype but psychedelics are like a reset switch – they let me resolve the stuff that’s been ruminating around in my brain. I start noticing the difference if it’s been over 3 months, but I don’t have psychotherapy with it – that being said typical psychotherapy doesn’t tend to work with autistic people, although there are people doing research into methods that can work on us.
https://onlinelibrary.wiley.com/doi/full/10.1002/capr.12675
I live near OSU, and they’re actually doing a research study on this. Unfortunately for me, I missed my chance to sign up.
What needs to happen for this to become a standard, physician lead, insurance covered treatment for mental health?